About Adequan® i.m.

Making strides for mobility

Over the past 30 years, Adequan® i.m. (polysulfated glycosaminoglycan) has been recommended millions of times1 to treat degenerative joint disease (DJD) in horses, and with good reason. Since approval in 1989, it’s been the only FDA-Approved equine PSGAG available, and the only one proven to: 2,3

  • Reduce inflammation
  • Restore synovial joint lubrication
  • Repair joint cartilage
  • Reverse the disease process
Adequan Equine horse legs running dust HR

INDICATIONS

Adequan® i.m. (polysulfated glycosaminoglycan) is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

There's nothing else like it

Understanding the difference between the many therapeutic options for DJD can make a real difference in a horse’s long-term joint health.

By reviewing the choices together, the horse owner and veterinarian can consider the treatment options available and decide the best course of action.*

It’s important to talk with your veterinarian to discover if Adequan® i.m. is the right treatment for your horse.

* The content of this educational brochure was developed as a reference guide and contains information on products that are currently being used within the equine industry.
Rx Pyramid

IMPORTANT SAFETY INFORMATION There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan. Studies have not been conducted to establish safety in breeding horses.

Because mobility matters

Mobility is a vital component to every horse’s health and well-being, so taking a proactive approach to diagnosis and treatment through each stage of life can help extend their mobility span.4 When you start with Adequan early and stay with it as needed, horses may enjoy greater mobility over a lifetime.5

Discover if Adequan® i.m. is the right choice.

Adequan Equine brown white horse legs on grass HR
INDICATIONS Adequan® i.m. (polysulfated glycosaminoglycan) is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
IMPORTANT SAFETY INFORMATION There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan. Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For full prescribing information, click here .
1. Data on File, American Regent Animal Health, Inc.
2. Burba DJ, Collier MA, DeBault LE, Hanson-Painton O, Thompson HC, Holder CL: In vivo kinetic study on uptake and distribution of intramuscular tritium-labeled polysulfated glycosaminoglycan in equine body fluid compartments and articular cartilage in an osteochondral defect model. J Equine Vet Sci 1993; 13: 696-703.
3. Adequan® i.m. Package Insert, Rev 1/19.
4. McFarlane D. "How to Establish a HealthCare Program for the Aging Horse in Equine Practice, " AAEP Proceedings, 62: 2016.
5. McIlwraith CW, Frisbie DD, Kawcak CE, van Weeren PR. Joint Disease in the Horse. St. Louis, MO: Elsevier, 2016; 33-48.

Let’s stay in touch

Be the first to hear about important news and product information!
First, select the one that best describes you.
Then we'll take you to our sign-up page.

EQUINE VETERINARY
PROFESSIONAL 		HORSE OWNER
CONTACT INFORMATION
Contact Us Adverse Event Reporting Product Quality Complaints Sign Up
MORE ABOUT ADEQUAN
Dosing & Administration Prescribing Information Safety Information Ordering Information
AMERICAN REGENT ANIMAL HEALTH
About Us Our Brands
Animal Health Logo
All trademarks are the property of American Regent, Inc.
©2022, American Regent, Inc.
PP-AI-US-0268 (v4.0) 01/2022